MAUNA KEA TECH : Surgeons successfully use Cellvizio for immediate confirmation of cancer in brain and spinal tumors

PARIS, France - August 25, 2015 - Mauna Kea Technologies (Euronext: MKEA; ISIN: FR0010609263, PEA- PME eligible), inventor of Cellvizio®, a multidisciplinary confocal laser endomicroscopy (CLE) platform, today announced that results of a new study involving the use of CLE with Cellvizio were published in the peer reviewed journal Neurosurgery*. Results showed that use of Cellvizio provides real time histomorphological diagnosis of pathology with results similar to use of traditional surgical biopsy. Diagnosis with conventional histology can take 5 to 10 days.
These results were initially presented at the Congress of Neurological Surgeons 2014 in Boston, MA, USA and were awarded with the National Brain Tumor Society Mahaley Clinical Research Award.
Siemens Corporate Technology provided support for the Cellvizio device used in this study during which fresh surgical biopsies of 150 intracranial and intraspinal lesions were examined to test the signal intensity and adequate contrast for Cellvizio imaging. A combination of ex vivo biopsies was compared to standard histology. Cellvizio yielded consistently high-quality histomorphology of brain and spinal tumors, allowing a
1000-fold magnification of observed tissue structures during surgery, whereas commonly used microscopy and standard endoscopy offer a 25-fold and 2-fold magnification respectively.
"Surgeons can face significant challenges in developing a precise assessment of tumor margins in brain tissue. The ability to differentiate tissue in real time with this level of magnification and precision is a very significant advantage," said Cleopatra Charalampaki, MD, PhD, department of neurosurgery at Hospital Merheim, Cologne Medical Center, Cologne, Germany. "These important new data provide strong validation of the mechanism of action of CLE with Cellvizio to support faster and more effective perioperative delineation between healthy and pathological tissue".
According to the research team led by Professor Charalampaki, potential benefits of use of Cellvizio-assisted surgery in diagnosis of brain and spinal tumors include immediate diagnosis to support faster post-operative disease management, and more effective delineation between healthy and pathological tissues that can lead to improvements in surgical resection and prognosis.
"This is yet another example of a high-quality investigator initiated study bringing to light a novel use of Cellvizio with high clinical and market potential. By providing surgeons with a tool to image brain tissue in real time, Cellvizio has the potential to completely transform the diagnosis and treatment of these tumors in the years ahead, leading to faster diagnosis, more accurate assessments of tumor margins, and improved surgical resections", said Sacha Loiseau, founder and CEO of Mauna Kea Technologies. "Importantly, these findings in the central nervous system also support the potential use of Cellvizio in the diagnosis and imaging of many other forms of cancer".

* Link to the article:

http://journals.lww.com/neurosurgery/Fulltext/2015/08001/Confocal_Laser_Endomicroscopy_for_Real_time.32.aspx

1

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company focused on protecting patient lives by enabling physicians and surgeons

to make better decisions thanks to direct visualization at the cellular level. The company's flagship product, Cellvizio® has received clearance for a broad range of applications in more than 40 countries including the United-States, Europe, Japan, China, Canada, Brazil and Mexico.

For further information on Mauna Kea Technologies, visit www.maunakeatech.com

Eric Cohen

Vice President Finance

Tél. : +33 (0)1 70 08 09 70

investor-vpf@maunakeatech.com

NewCap - Investor Relations Florent Alba / Pierre Laurent Tél. : +33 (0)1 44 71 94 94 maunakea@newcap.fr

Berry & Company Public Relations

Bill Berry

Tel: +1 212 253 8881 bberry@berrypr.com

2

distributed by